1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Compliance

2021 Forecast Includes Rise In FDA Enforcement Actions

 
• By Elizabeth Orr

The Biden administration may take a heavier hand with manufacturers than we saw in recent years, attorneys say.

Continuing fallout from the COVID-19 pandemic, user-fee negotiations and potential legislative action are among the device regulatory areas two attorneys from the law firm Paul Hastings expect to be paying close attention to during the coming year.

During a 28 January webinar, the attorneys said to watch any moves on remote inspections from the US Food and Drug Administration. The agency has been reluctant to conduct them...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.